4.5 Article

Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses

Journal

VACCINE
Volume 34, Issue 51, Pages 6464-6471

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2016.11.026

Keywords

Influenza; H7N9; LAH-HBc VLP; Adjuvant

Funding

  1. Cooperative Innovation Center of Engineering and New Products for Developmental Biology of Hunan Province [20134486]
  2. Open Fund of Innovation Platform for Colleges and Universities of Hunan [11040]
  3. National Natural Science Foundation of China [81172738]
  4. Chinese State Key Project Specialized for Infectious Diseases [2013ZX10004003003]
  5. National Key Subject of Drug Innovation [2015ZX09304004-004]
  6. Shanghai Science and Technology Support Program, China [15431906500]
  7. Teacher Research Fund of Central South University [2014JSJJ037]

Ask authors/readers for more resources

The long alpha-helix (LAH) region located in influenza virus hemagglutinin (HA) shows conservation among different influenza A strains, which could be used as a candidate target of influenza vaccines. Moreover, the hepatitis B virus core protein (HBc) is a carrier for heterologous epitopes in eliciting effective immune responses. We inserted the LAH region of H7N9 influenza virus into the HBc and prepared the LAH-HBc protein, which were capable of self-assembly into virus-like particles (VLP), by using E. coli expression system. Intranasal immunization of the LAH-HBc VLP in combination with chitosan adjuvant or CTB* adjuvant in mice could induce both humoral and cellular immune responses effectively and provide complete protection against lethal challenge of homologous H7N9 virus or heterologous H3N2 virus, as well as partial protection against lethal challenge of heterologous H1N1 virus. These results provide a proof of concept for LAH-HBc VLP vaccine that would be fast and easy to be produced and might be an ideal candidate as a rapid-response tool against a future influenza pandemic. (C) 2016 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available